TVRD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

TVRD ▼ -30.86% at T+20d

NEUTRAL call ✗ call lost -30.86% · α vs SPY -30.88% · entry $4.18 → $2.89

Next anchor: T+60d in 7w

Last close $2.64 (close Jun 12) · -36.84% from $4.18 entry

Entry anchored
May 7, 03:56 PM ET
via Databento tick

T+1d

-5.26%

call -5.26% · α -5.50%

$3.96

settled 5w ago

T+5d

-5.26%

call -5.26% · α -6.73%

$3.96

settled 4w ago

T+20d

-30.86%

call -30.86% · α -30.88%

$2.89

settled 7d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The company highlighted upcoming catalysts: TTI-109 Phase 1 healthy volunteer data expected in June 2026 and TTI-101 Phase 2 HCC topline data in 2H 2026. Cash runway extends into Q4 2026, but net loss widened to $6.8M from $4.4M in operating expenses, and the stock has historically not reacted positively to prior filings (0% win rate at T+20).

Actionable Insight

Monitor TTI-109 topline data in June 2026 as a key catalyst; the stock has historically not responded positively to prior filings (0% T+20 win rate), so any bullish reaction may be short-lived. Cash runway into Q4 2026 suggests no near-term dilution risk, but the company will likely need to raise capital before mid-2027.

Key Facts

Q1 2026 EPS: -$0.73 vs consensus -$0.72 (1.4% miss, in-line)
No revenue reported (pre-revenue clinical-stage biotech)
Net loss of $6.8M vs $9.6M in Q1 2025 (improved due to prior year's $5.5M other expense)
Operating expenses increased to $7.1M from $4.4M (R&D up 58%, G&A up 72%)
Cash and short-term investments: $25.0M as of March 31, 2026, down from $30.8M at Dec 31, 2025
Cash runway sufficient through Q4 2026
TTI-109 Phase 1 healthy volunteer topline data expected June 2026
TTI-101 Phase 2 HCC topline data expected 2H 2026
Historical T+20 win rate on prior TVRD filings: 0% (n=2 settled)

Financial Impact

Net loss of $6.8M in Q1 2026; cash burn of ~$5.8M per quarter; $25.0M cash runway into Q4 2026

epscashoperating expenses

Risk Factors

TTI-109 or TTI-101 clinical trial failures could severely impact stock price
Cash runway only through Q4 2026; likely need for additional financing
Historical poor stock performance on prior filings (negative alpha at T+20)
No revenue and increasing operating expenses

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

64% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3290997

5 reports for TVRD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for TVRD — sortable, filterable
	Type				Now
May 14, 2026 4w ago	EFFECT BEARISH ★ 6/10	$3.96 $3.59	▲ +9.34%	▲ +8.63%	$2.64 (+33.33%)
May 13, 2026 4w ago	EFFECT BEARISH ★ 7/10	$3.95 $3.71	▲ +6.08%	▲ +4.92%	$2.64 (+33.16%)
May 8, 2026 5w ago	Press Release NEUTRAL ★ 4/10	$4.18 $3.96	▼ −5.26%	▼ −6.73%	$2.64 (−36.84%)
Apr 23, 2026 7w ago	DEFA14A NEUTRAL ★ 2/10	$3.10 $3.15	▲ +1.61%	▲ +0.70%	$2.64 (−14.84%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$3.00 $2.96	▼ −1.33%	▼ −5.10%	$2.64 (−12.00%)

US Market Status

Market Closed — Opens in 4h 42m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access